Kornimate/medical-research-clean huggingface dataset:
national study of adrenal tumours

Conditions: Pheochromocytoma and Paraganglioma (PPGL); Adrenocorticol Cancer (ACC); Adrenal Tumours

Summary: this is a study putting together large numbers of patients with or without a hereditary risk of adrenal tumours including tumours such as adrenocortical carcinoma and phaeochromocytoma/paraganglioma. the purpose is to answer questions about the survival of patients with these rare tumours and to do this, we will collect information on diagnosis and management of these tumours. this data will be best assessed by combing these rare cases at a national level recruiting from centres throughout uk and ireland. the information will be confidential and stored in a secure platform. patients will be approached for consent to gather their data by their local consultants and patients will have the choice to participate or decline participation, which will not affect their standard of care treatment.


Eligibility criteria:
inclusion criteria: 1. patients with a confirmed diagnosis of phaeochromocytoma or paraganglioma or adrenocortical tumour based on histology and or biochemical testing including plasma or urine metanephrine's or a urine steroid profile and confirmatory imaging tests or patients with a confirmed pathogenic variant in a known ppgl predisposition gene 2. patient is willing and able to give informed consent for the participation in the study. 3. male or female, and over the age of 18. 4. patient, in the investigator's opinion, is able and willing to comply with all the study requirements. 5. patients held on local hospital audit notes who have had a diagnosis of phaeochromocytoma or paraganglioma or adrenocortical tumour based on histology and or biochemical testing including plasma or urine metanephrine's or a urine steroid profile and confirmatory imaging tests or patients with a confirmed pathogenic variant in a known ppgl predisposition gene who are now deceased and have been deceased prior to the start of the study. exclusion criteria: 1. alive patients unable to give informed consent will not be recruited 2. patients with an unconfirmed diagnosis of phaeochromocytoma or paraganglioma or adrenocortical tumour based on histology and or biochemical testing including plasma or urine metanephrine's or a urine steroid profile and confirmatory imaging tests or patients with unconfirmed pathogenic variant in a known ppgl predisposition gene
study to confirm the safety and efficacy of tegoprazan in patients with healed erosive esophagitis

Conditions: Healed Erosive Esophagitis

Summary: this study is designed to confirm the non-inferiority of tegoprazan 25mg, compared to lansoprazole 15mg as maintenance therapy in patients with healed erosive esophagitis confirmed by endoscopy following oral administration once daily(qd) for 6 months.

this is a double blind, randomized, active-controlled, phase 3 study. subjects will be randomly assigned to one of the two treatment groups (tegoprazan 25mg, lansoprazole 15mg).

Eligibility criteria:
inclusion criteria: 1. erosive eshophagitis(la classification grades a to d) within 12 weeks prior to randomization 2. healed erosive esophagitis within 7 days prior to randomization 3. no heartburn and regurgitation within 7 days prior to randomization exclusion criteria: 1. unable to undergo upper gi endoscopy 2. presence of esophageal stricture, ulcerated stricture, gastroesophageal varix, long segment barrett's esophagus with \>3 cm length(lsbe), active digestive ulcer, gastric bleeding or malignant tumors on an upper gi endoscopy 3. diagnosed with primary esophageal motility disorder, irritable bowel syndome(ibs) or inflammatory bowel disease(ibd) 4. history of acid-suppressive, esophageal or gastric surgeries
compassionate use study of 125 mg per day of azimilide dihydrochloride in one patient

Conditions: Congestive Heart Failure

Summary: this is an open-label, long term compassionate use study of 125 mg per day of azimilide 2hcl in a patient who completed two other protocols (2000098 and 2001060.


Eligibility criteria:
inclusion criteria: * no inclusion criteria as the patient to be included is this compassionate use protocol is currently receiving azimilide therapy exclusion criteria: * currently taking class i or other class iii antiarrhythmic drug or other drugs that may prolong qt interval. * is unwilling or unable to give or understand informed consent.

Keywords: patients with icd
casodex/zoladex biomarkers in localised prostate cancer

Conditions: Prostate Cancer

Summary: to evaluate anti-androgen (bicalutamide) induced biological and molecular changes in prostate comparison to chemical castration induced (goserelin) ones


Eligibility criteria:
inclusion criteria: 1. histologically confirmed localised prostate biopsy specimen that contains sufficient tumour for evaluation of cell proliferation and apoptosis markers 2. patients who are scheduled for radical prostatectomy with curative intents

Keywords: biomarker study patients with clinically localised prostate cancer
a trial of two diets for weight and diabetes management

Conditions: Type 2 Diabetes Mellitus; Obesity

Summary: the purpose of this study is to determine whether a low-fat or low-glycemic load diet is more effective for controlling weight and blood glucose in persons with type 2 diabetes.

this research is a randomized controlled trial to compare long-term outcomes behavioral weight loss interventions that include either low-fat or low-glycemic load dietary instruction. targets for energy intake and expenditure, and behavioral skills taught, are identical across the two diets. additionally, both treatments include 20 weekly group sessions, followed by 10 every-other-week sessions. participants are overweight and obese adults with type 2 diabetes. the primary outcomes are changes in weight and glycated hemoglobin. those randomized to the low-glycemic load diet are expected to achieve greater weight losses and maintain better glycemic control at the end of treatment (i.e., week 40) and after 1 year of no-treatment follow-up (i.e., week 92).

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * body mass index (bmi) of 27 to 45 kg/m2 with weight \</= 136 kg (300 lbs. * capacity to provide written informed consent * systolic blood pressure between 90 and 160 mm hg, inclusive. * diastolic blood pressure between 65 and 100 mm hg, inclusive. * resting heart rate between 65 and 90 beats per minute, inclusive. exclusion criteria: * a recent (i.e., within 1 year) myocardial infarction * unstable angina * malignant arrhythmias * history of cerebrovascular, renal, or hepatic disease * history of seizures * protein wasting diseases (e.g., cushing's syndrome) * uncontrolled hypertension (\> 160/100 mm hg) * type 1 diabetes * uncontrolled thyroid disease * pregnancy or lactation * electrolyte abnormalities * clinically significant psychosocial impairment (principally, major depression) * treatment with steroids

Keywords: obesity type 2 diabetes glycemic load weight loss glycated hemoglobin
effects of dapagliflozin on progression of alport syndrome

Conditions: Alport Syndrome

Summary: recently, a series of large clinical trials have confirmed the cardio-renal protective effects of sodium-glucose cotransporter 2 (sglt2) inhibitors. but few patients with hereditary nephritis were included in these studies. this study is to evaluate the effects of dapagliflozin on slowing kidney disease progression in patients with alport syndrome.


Eligibility criteria:
inclusion criteria: * histologic or genetic confirmation of alport syndrome; * egfr ≥ 30 ml/min/1.72m2; * proteinuria \> 0.5 g/24 h; * use of an ace inhibitor or arb, dose stable for more than 4 weeks; exclusion criteria: * concurrence of other types of kidney disease; * type 1 or type 2 diabetes; * use of other types of sodium-glucose cotransporter 2 inhibitors within the month prior to enrollment, or prior allergy to such drugs; * acei combined with arb, or direct renin inhibitors, aldosterone receptor antagonists; * uncontrolled hypertension (blood pressure greater than 160/90 mmhg during screening); * patients undergoing renal transplantation or maintenance dialysis treatment; * coexist with other serious and/or unstable diseases, such as serious cardiovascular diseases, respiratory diseases, liver diseases or neuropsychiatric diseases; * patients who are participating in clinical trials of other drugs; * pregnant or lactating women, or patients who do not want to receive contraception.
clinical study of targeted cryoablation therapy in the treatment of hepatic carcinoma

Conditions: Liver Neoplasms

Summary: the purpose of this study is to evaluate the safety and efficacy of targeted cryoablation therapy for hepatic carcinoma.

a cryoprobe is inserted percutaneously under ct guidance into the targeted lesion. patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 10-6-10minutes.

Eligibility criteria:
inclusion criteria: * diagnosis of liver cancer based on histology or the current accepted radiological measures. * single tumor size ≤5.0 cm in greatest diameter, or multiple tumor number≤3 and each tumor size≤ 3cm. * life expectancy: greater than 3 months. * patients' liver function is child-pugh a or b. * ability to understand the study protocol and a willingness to sign a written informed consent document. * unable to receive operative surgery. exclusion criteria: * patients with other primary tumor except liver cancer. * history of coagulation disorders or anemia.
effects of complex training on pain and posture in school going children with heavy bags packs

Conditions: Posture Disorders in Children

Summary: as the issues of related to heavy bag packs are increasing with every day so the complex training program along with postural training may prove to be an effective protocol in dealing with issues


Eligibility criteria:
inclusion criteria: * children with age between 12 to 15 years. * children with normal bmi (5th - 85th percentile). * students carrying bags with 15% of body weight. exclusion criteria: * children with any physical disability ( spinal cord injury, cerebral palsy, multiple sclerosis, and epilepsy) * children using single-strap bags. * one-sided shoulder elevation. * children using handbags or trolley bags.

Keywords: abnormal posture back pain improper backs use physical exercise
azilsartan in patients with diabetic kidney disease and hypertension

Conditions: Proteinuria; Kidney Dysfunction; Blood Pressure; Diabetic Kidney Disease

Summary: hypertension is the most common complication in patients with diabetes nephropathy. strengthening blood pressure and blood sugar control is the basic treatment for patients with diabetes nephropathy. angiotensin receptor blocker (arb) and angiotensin-converting enzyme inhibitor (acei) are the first line drugs recommended in domestic and international guidelines for diabetes patients to control hypertension. as a new arb drug, azilsartan has been found to have better antihypertensive effect than other arb drugs. however, due to the limited sample size and study time, azilsartan has no significant advantage over other arb drugs in terms of renal protection effect, and has not been systematically studied in diabetes nephropathy population. this study is intended to evaluate the effect of azilsartan on proteinuria and blood pressure improvement in patients with diabetes nephropathy and hypertension through clinical randomized controlled study, so as to accumulate evidence-based evidence of azilsartan in the comprehensive management of heart and kidney protection in this group of people, and promote the development of comprehensive treatment for patients with metabolic disease and renal injury combined with hypertension. this study will compare the advantages and disadvantages of azilsartan and classical arb drug losartan potassium in terms of proteinuria, blood pressure control and renal function protection in patients with diabetes nephropathy and hypertension; we propose that the main indicator is the change of urinary albumin/creatinine ratio relative to the baseline, and the secondary indicator is the change of 24-hour urinary protein relative to the baseline; change of blood pressure relative to baseline; renal function, electrolyte and blood glucose.


Eligibility criteria:
inclusion criteria: * age 30 to 70; * type 2 diabetes diagnosed according to american diabetes association guidelines has stable blood sugar control, and glycosylated hemoglobin is less than 7.5%; * the patient's blood pressure systemic blood pressure (sbp) \>140 or diastolic blood pressure (dbp) \>90 mmhg, has not taken antihypertensive drugs or is taking non-arb/acei antihypertensive drugs; * urine albumin/creatinine ratio\>300mg/g. exclusion criteria: * type 1 diabetes; * the patient is considered as non-essential hypertension, such as hypertension caused by renal hypertension or endocrine disease; * contraindications of arb drugs, such as pregnancy status, bilateral renal artery stenosis, allergy to arb drugs and their excipients; * it is expected that dialysis treatment will be carried out within 6 months; * patients with malignant tumors; * patients with mental illness; * the researcher believes that others are not suitable for this study.

Keywords: diabetic kidney disease hypertension
weight-bearing recommendation after replacement of the hip or knee joint

Conditions: Osteoarthritis

Summary: despite the widespread use of total hip and knee arthroplasty, there is a notable lack of consensus regarding postoperative treatment, mostly because of the lack of well-designed studies testing the efficacy and effectiveness of such practices. in particular, there are no evidence-based recommendations on the amount of weight that the patient should be advised to bear on the operated leg after the operation.


Eligibility criteria:
inclusion criteria: * patient who is about to receive unilateral hip or knee replacement surgery on an elective basis for diagnosis of osteoarthritis or femoral head necrosis exclusion criteria: * a history of septic arthritis, * hip fracture, * intraoperative complications, * history of implant surgery on the joint to be operated on, * rheumatoid arthritis, * amputations, * inability to complete the questionnaires because of cognitive or language difficulties.

Keywords: total hip arthroplasty tha total knee arthroplasty tka total hip replacement thr total knee replacement tkr
analgesic use for pain relief in scorpion sting

Conditions: Scorpion Stings

Summary: in scorpion stings, patients mostly apply with the complaint of pain. emergency physicians need to relieve this pain quickly.

aim: in this study, the analgesic efficacy of intravenous (iv) paracetamol, iv dexketoprofen trometamol and topical lidocaine will be compared in patients presenting with pain after scorpion sting. methods: this study is a double-blind, randomized, placebo-controlled study conducted in a tertiary emergency department. adult patients who applied to the study with no systemic findings after scorpion sting and especially with pain will be randomly assigned to one of 4 groups: iv paracetamol, iv dexketoprofen trometamol, topical lidocaine or placebo. in order to determine the intensity of pain, visual analog pain score (vas) will be measured at the time of admission to the emergency department, at the 30th minute and at the 60th minute. afterwards, the vas score changes between the groups will be compared.

Eligibility criteria:
inclusion criteria: * patients aged 18 and over * scorpion sting with pain * the diagnostic criteria of grade 1 for scorpion sting exclusion criteria: * patients who denied to give informed consent * taking analgesic treatment (ice application or drugs etc.) in the last 6 hours * any symptoms and findings of systemic toxicity of scorpion sting * pregnant women * hemodynamically unstable patients * known allergy to drugs of the study * patients with renal disease * the cases that passed more than 6 hours after the bite
iron absorption from gds capsules

Conditions: Iron Deficiency

Summary: slow release iron capsules have been designed based on the gastric delivery system. iron absorption from those capsules administered with and without meals will be measured using stable iron isotopes.


Eligibility criteria:
inclusion criteria: * female, * age 18-50 years, * max. body weight 65 kg, * serum ferritin \< 35µg/l exclusion criteria: * pregnancy, * lactation, * regular intake of medication, * blood donation or significant blood losses over the past 4 months
evaluating artificial intelligence-based clinical decision support for sepsis and ards

Conditions: Sepsis; Acute Respiratory Distress Syndrome (ARDS)

Summary: sepsis and acute respiratory distress syndrome (ards) are common in intensive care units. managing sepsis and ards is inherently complex and requires making numerous decisions under uncertainty. artificial intelligence (ai) clinical decision support systems (cdsss) offer a promising approach to support care management for sepsis and ards. the goal of this randomized, survey-based study is to compare treatment recommendations enacted by clinicians to those generated by an ai cdss. the study will investigate whether an ai cdss can generate treatment recommendations that are safe, appropriate, and indistinguishable to those provided by real clinicians. in this study, participants (i.e., critical care clinicians) will review a series of critical care cases (vignettes) in an electronic survey. each vignette will contain a de-identified case of a patient with sepsis and ards as well as treatment recommendations for the case. participants will assess the safety and appropriateness of each treatment recommendations and answer whether they think the treatment recommendations came from the clinician or an ai cdss.


Eligibility criteria:
inclusion criteria: * working as a physician (i.e., md, do) or an advanced practice provider (i.e., nurse practitioner, physician assistant) * working at a hospital or medical center in medical critical care, anesthesia critical care, surgical critical care, or emergency medicine exclusion criteria: * has not completed a residency training program (i.e., medical intern or resident)

Keywords: sepsis acute respiratory distress syndrome clinical decision support clinical decision support system invasive mechanical ventilation artificial intelligence
molecular diagnosis of respiratory viral infections on sputum from cystic fibrosis patients

Conditions: Cystic Fibrosis; Acute Respiratory Infection

Summary: the main objective of this project is to evaluate the agreement between nasopharyngeal and sputum specimens in terms of detection of viral infection in cystic fibrosis (cf) participants.this is a 12-month national, multicenter prospective study (7 centers). inclusions concern cf participants (children or adults) with signs of acute respiratory infection seen in consultation or hospitalized in their cf research center. a molecular viral multiplex search is performed on both nasopharyngeal and expectoration collected samples for each included participant. determination of viral detection agreement between the two cf respiratory samples is then performed.

viral respiratory infections in cystic fibrosis (cf) have a significant impact on the progression of the disease. it is therefore essential to look for these viruses. no recommendations are made for the virological follow-up of cf patients and no optimal strategy for the type of sampling required. in non-cf patients, the search for a viral infection is performed by nasopharyngeal sampling. this method of sampling is invasive and uncomfortable for the patient. in cf patients, sputum, non-invasive sampling, is routinely used for bacterial research and may be used for viral infections to avoid invasive nasopharyngeal sampling in patients whose management is heavy. after giving consent, both sputum and nasopharyngeal swab are collected for each participant. a record of clinical and biological data is also made at inclusion. a molecular viral search is performed on both samples by a multiplex technique detecting a broad spectrum of respiratory viruses. a bacteriological analysis is carried out on sputum. the molecular results will be interpreted blindly according to the main criterion of evaluation, presence or absence of viral infection. comparison of expectoration to nasopharyngeal sampling of cf patients for respiratory virological diagnosis should analyse agreement of the molecular viral detection and position cf sputum as an optimal assay for respiratory viruses with the advantage of not being invasive and in all cases routinely taken for the control and bacterial follow-up. the promotion of sputum as an ad hoc sampling for viral research and epidemiology would facilitate the establishment of surveillance for viral infections in cystic fibrosis and thereby contribute to the cf register data.

Eligibility criteria:
inclusion criteria: * participant with cystic fibrosis * participant with sign of acute respiratory infection * participant able to expectorate exclusion criteria: * participant not able to expectorate * participant refusing to participate

Keywords: cystic fibrosis sputum nasopharyngeal swab viral molecular diagnosis respiratory infection expectoration
evaluation for restoration of erectile dysfunction after cardioversion treatment trial

Conditions: Erectile Dysfunction

Summary: erectile and cognitive function by using the questionnaire and assessment form before sinus conversion

sinus conversion by electrical cardioversion increase cardiac output and systemic perfusion. according to recent reports, maintenance of sinus rhythm increase systemic perfusion which leads to improve renal function. therefore, we hypothesized that sinus conversion of patients with atrial fibrillation will increase systemic perfusion which might improve the erectile dysfunction and cognitive dysfunction.

Eligibility criteria:
inclusion criteria: * patients scheduled to electrical cardioversion exclusion criteria: * patients have taken any medication for erectile dysfunction or who have got any operation already or are scheduled to do. * more than moderate degree of cognitive dysfunction

Keywords: erectile dysfunction cognitive function